Skip to main content

Table 3 Comparisons of mean utilities among subgroups.

From: Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study

 

Age

Sex

Knowledgeable about leukaemia

 

<60 years

(N = 63)

≥60 years

(N = 26)

Male

(N = 39)

Female

(N = 50)

Yes

(N = 23)

No

(N = 66)

Health State

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Complete Response

0.92 ± 0.09

0.88 ± 0.13

0.92 ± 0.08

0.89 ± 0.12

0.90 ± 0.13

0.91 ± 0.10

Partial Response

0.84 ± 0.14

0.84 ± 0.14

0.87 ± 0.10

0.82 ± 0.16

0.83 ± 0.17

0.85 ± 0.13

No Change

0.78 ± 0.14

0.80 ± 0.16

0.80 ± 0.13

0.77 ± 0.15

0.78 ± 0.17

0.79 ± 0.14

Progressive Disease

0.69 ± 0.19

0.65 ± 0.23

0.69 ± 0.18

0.67 ± 0.22

0.67 ± 0.23

0.68 ± 0.19

NC + 1-2 Nausea

0.72 ± 0.19

0.74 ± 0.12

0.73 ± 0.14

0.72 ± 0.19

0.76 ± 0.15

0.72 ± 0.18

NC + 1-2 Nausea/Vomiting

0.73 ± 0.16

0.73 ± 0.15

0.75 ± 0.14

0.71 ± 0.17

0.71 ± 0.15

0.73 ± 0.16

NC + 1-2 Diarrhea

0.70 ± 0.21

0.71 ± 0.14

0.70 ± 0.18

0.71 ± 0.20

0.67 ± 0.19

0.71 ± 0.19

NC + 3-4 Anemia

0.70 ± 0.19

0.65 ± 0.17

0.69 ± 0.16

0.68 ± 0.20

0.72 ± 0.21

0.67 ± 0.18

NC + 3-4 Pyrexia

0.66 ± 0.18

0.68 ± 0.15

0.66 ± 0.16

0.67 ± 0.18

0.64 ± 0.14

0.67 ± 0.18

NC + 3-4 Pneumonia

0.59 ± 0.20

0.58 ± 0.17

0.59 ± 0.19

0.58 ± 0.20

0.55 ± 0.19

0.59 ± 0.20

Second-line Treatment

0.71 ± 0.17

0.72 ± 0.16

0.74 ± 0.15

0.69 ± 0.18

0.69 ± 0.18

0.72 ± 0.16

Third-line Treatment

0.65 ± 0.23

0.63 ± 0.20

0.66 ± 0.17

0.64 ± 0.26

0.63 ± 0.24

0.65 ± 0.21

  1. Note: No differences within subgroups statistically significant (p < 0.05; Student's t test)